Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article reviews research on the treatment of benign prostatic hyperplasia and suggests that 5-alpha-reductase inhibitors like finasteride may improve therapeutic outcomes, without providing new clinical results.

In this study, indications for monotherapy with 5-alpha-reductase inhibitors, such as finasteride and herbal drugs, were developed based on clinical and morphological changes in patients with benign prostatic hyperplasia.

This study explores the clinical significance of the intravesical prostatic protrusion/prostate volume ratio in diagnosing bladder outlet obstruction but reports no new results.

This study found that long-term administration of tamsulosin hydrochloride 0.2 mg is effective, safe, and well-tolerated for improving symptoms and quality of life in patients with LUTS of BPH.

This study found that adolescent men in Ireland are more likely to prefer keeping a baby over abortion in a hypothetical unplanned pregnancy, influenced by their anticipated regret and perceived familial attitudes.

This study found that patients with BPH who received finasteride before TURP experienced reduced intraoperative blood loss and improved quality of life one month after surgery compared to those who did not.

The authors concluded that components of metabolic syndrome were strongly associated with severe lower urinary tract symptoms in Latin American men, while alopecia was not an independent predictor.

This study found that Thermobalancing therapy using Dr Allen's Device significantly improved symptoms and quality of life in men with benign prostatic hyperplasia, but larger prostate sizes may require longer treatment.

This research overview discusses Post-Finasteride Syndrome, presenting data from an FDA database, but it does not report any new clinical findings.

Men's age, urinary symptoms, and heart health risks create different types of erectile dysfunction.

Some patients may experience lasting sexual dysfunction, depression, and other side effects from 5α-reductase inhibitor therapy.

Larger prostate size in older men may be linked to poorer semen quality and fertility issues.

This review critically examines the current medical management strategies for BPH/LUTS and reports no new experimental results.

This study demonstrates that patients with benign prostatic hyperplasia have a higher severity and frequency of male pattern baldness compared to a control group.

This review analyzes the potential mechanisms by which SARS-CoV-2 may exacerbate symptoms of benign prostatic hyperplasia and suggests a connection via ACE2 and androgen receptor pathways; it reports no new clinical results.

This review summarizes a meta-analysis suggesting that finasteride is most effective for improving symptoms and urinary flow in men with large prostates experiencing benign prostatic hyperplasia.

This study found that long-term dutasteride therapy in men with benign prostatic hyperplasia worsened erectile dysfunction, reduced testosterone levels, and increased blood glucose and lipid profile, indicating negative metabolic impacts.

This study found that combining 5-alpha reductase inhibitors with alpha-blockers provided the best symptomatic relief and reduced the risk of clinical progression for BPH, while PDE5 inhibitors could offset sexual side effects.

This study found that a transdermal delivery system using 3% azone and P407 gel may enhance the skin permeation of doxazosin and finasteride for treating benign prostatic hyperplasia.

This study evaluated potential penile vascular changes and persistent adverse effects in men discontinuing 5α-reductase inhibitors for androgenic alopecia, but no new clinical results were reported.

This study found that while new treatments like Optilume, Rezum, and Aquablation have minimal risks of sexual dysfunction, they offer less improvement in lower urinary tract symptoms compared to traditional surgeries like TURP, though Aquablation does reduce ejaculatory dysfunction more effectively than TURP.

This study found that six weeks of finasteride therapy before TURP reduced intraoperative blood loss and improved early postoperative quality of life in patients with benign prostatic hyperplasia.

This review explores the potential impact of SARS-CoV-2 on benign prostatic hyperplasia and related lower urinary tract symptoms but reports no new clinical results, emphasizing the need for further studies to quantify these changes.

This study reported that cognitive biopsy diagnosed prostate cancer in 44% of patients with at least one previous negative biopsy, with higher detection rates in lesions classified as PI-RADS 4 and 5.

This abstract discusses treatment options for benign prostatic hyperplasia and provides no new clinical results.

This article reviews treatment-induced sexual dysfunctions related to 5-alpha-reductase inhibitors and reports no new results; it highlights the need to better define and understand this controversial topic.

Higher CRP levels suggest chronic inflammation is linked to bladder-related urinary symptoms in men with enlarged prostates.

Men with early balding may have a higher risk of prostate issues, and surgery for prostate cancer has a slight survival benefit over radiation.

This study aimed to estimate the value of urine prostate specific antigen (uPSA) as a marker for benign prostatic hyperplasia (BPH) but reported no new clinical findings.

This study reports on biofeedback treatment for dysfunctional voiding in three adult cases, providing insights into this condition when diagnosed beyond childhood.